Is NCT06996782 recruiting in Cleveland, OH?

Yes, NCT06996782 is currently recruiting participants at its Cleveland, OH location. This lung cancer clinical trial is actively enrolling qualified participants.

How do I join the lung cancer clinical trial in Cleveland?

To join this clinical trial in Cleveland, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Cleveland clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Lung Cancer Clinical Trial in Cleveland, OH

Who Can Participate

Inclusion Criteria

Participants with confirmed squamous or non-squamous NSCLC with a current Stage IV mNSCLC.

Provision of acceptable archival tumour tissue (or fresh tumour tissue biopsy if archival tumour tissue is not available and if clinically feasible) is mandatory at screening.

Measurable disease as defined by at least one lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter.

Minimum life expectancy of 12 weeks in the opinion of the investigator.

Adequate organ and marrow function.

Contraceptive use by male or female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Adequate organ and marrow function. Inclusion Criteria for Sub Study 2:

Programmed death-ligand 1 (PD-L1) tumour proportion score (TPS) ≥ 1% (per local report).

Adequate coagulation and urinalysis.

Minimum body weight of 30 kg.

Exclusion Criteria

Participants with epidermal growth factor receptor mutations, anaplastic lymphoma receptor fusions or any other known genomic alteration for which targeted therapy is approved in the first line per local standard of care.

Presence of small cell and neuroendocrine histology components.

Any severe or uncontrolled systemic diseases, including uncontrolled hypertension, and active bleeding diseases, ongoing or active known infection; interstitial lung disease/pneumonitis (of any grade); unstable and/or symptomatic venous thromboembolism, serious chronic gastrointestinal conditions associated with diarrhoea, active non-infectious skin disease or substance abuse.

Has had a prior stem cell, bone marrow, allogenic tissue, or solid organ transplant.

Has an active autoimmune disease that has required systemic treatment in the past 5 years.

History of clinically significant arrhythmia, cardiomyopathy of any aetiology or symptomatic congestive heart failure.

History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention or presence of small cell and neuroendocrine histology components.

Persistent toxicities (common terminology criteria for adverse events \[CTCAE\] ≥ Grade 2) caused by previous anti-cancer therapy, excluding alopecia.

Spinal cord compression or symptomatic brain metastases.

Treatment with any other anti-cancer agents or immunosuppressive medication.

Palliative radiotherapy with a limited field of radiation within 2 weeks or with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks, prior to the first dose of study intervention. Exclusion Criteria for Sub Study 2:

Known active hepatitis A.

Acute hepatitis B infection (anti-hepatitis B core antibody \[HBc\] immunoglobulin M \[IgM\] positive) or chronic hepatitis B infection with HBV DNA ≥ 2000 IU/mL.

Active hepatitis C infection (anti-HCV positive with HCV RNA detectable) or anti- HCV positive with HCV RNA undetectable for less than 12 weeks following treatment for HCV.

Known human immunodeficiency virus (HIV) infection that is not well controlled.

Evidence of Grade ≥ 1 central nervous system (CNS) haemorrhage.

Uncontrolled arterial hypertension ≥ 150 mm Hg (systolic) and/or ≥ 100 mm Hg (diastolic).

Has radiologically documented evidence of major blood vessel invasion or encasement by cancer, or major airway invasion by cancer or intra-tumour cavitation.

Has experienced any arterial thrombotic event, a Grade ≥ 3 bleeding event or has gross haemoptysis.

Has significant bleeding disorders, serious or nonhealing wound, ulcer or clinically relevant congestive heart failure.

Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection.

Has cirrhosis at a level of Child-Pugh B (or worse), or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.

Prior systemic therapy received for advanced or mNSCLC.

Prior exposure to an anti-T-cell immunoreceptor with Ig and Immunoreceptor Tyrosine-based Inhibition Motif domains (TIGIT) therapy or immune-oncology agent such as anti-programmed cell death protein 1 (PD-1), anti-PD-L1, or anti-cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), or any other anti-cancer therapy targeting immune-regulatory receptors or mechanisms.

Chronic therapy with antiplatelet agents.

Prior exposure to anti-vascular endothelial growth factor (VEGF) therapy.

Medical contraindication to protocol-specified platinum doublet regimens or ramucirumab.

Known allergy or hypersensitivity to rilvegostomig or any of the excipients of rilvegostomig, cisplatin, carboplatin, paclitaxel or nab-paclitaxel or pemetrexed or ramucirumab.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT06996782) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lung Cancer Treatment Options in Cleveland, OH

If you're searching for lung cancer treatment options in Cleveland, OH, this clinical trial (NCT06996782) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lung cancer clinical trials near you to find additional studies recruiting in your area.

Lung Cancer Clinical Trial in Cleveland, OH

Expert Care in Cleveland

IRB Approved

No-Cost Care

Apply for This Cleveland Location

Why Participate?

Simple Process

About This Lung Cancer Study in Cleveland